Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ESMO Symposium on Immuno-Oncology 2013

Who has already signed up for the Immuno-Oncology 2013 Conference?

ESMO gratefully acknowledges the valuable contribution of the following organisations*:

Platinum sponsor

Bristol-Myers Squibb

Route 206 and Province Line Road
08543 Princeton New Jersey
United States of America     
Tel : + 33 (0)1 58 83 60 00 (Europe)
 Fax : + 33 (0)1 58 83 60 01 (Europe)
Web: www.bms.com

Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. Our medicines are helping millions of people around the world in their fight against cancer, cardiovascular disease, diabetes, hepatitis B, HIV/AIDS, psychiatric disorders and rheumatoid arthritis. This event is supported by an unrestricted medical education grant from BMS.

Gold sponsor

F.Hoffmann-La Roche

Roche logo

Grenzacherstrasse 124
4070, Basel
Switzerland
Tel: +41 61 688 11 11       
Fax: +41 61 691 93 91
Web: www.roche.com

Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, infectious diseases, inflammation, metabolism and neuroscience. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Roche’s personalised healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2012 Roche had over 82,000 employees worldwide and invested over 8 billion Swiss francs in R&D. The Group posted sales of 45.5 billion Swiss francs. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.